Absci Corporation (ABSI)
(Delayed Data from NSDQ)
$3.97 USD
-0.14 (-3.41%)
Updated Jul 19, 2024 04:00 PM ET
Pre-Market: $4.01 +0.04 (1.01%) 9:26 AM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ABSI 3.97 -0.14(-3.41%)
Will ABSI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ABSI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABSI
Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
ABSI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Other News for ABSI
Absci management to meet with Truist
Absci management to meet with Truist
Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TD Cowen Keeps Their Buy Rating on AbSci (ABSI)